A Single-center, Open-label, Drug-drug Interaction Study of XZP-3287 Tablets in Healthy Subjects

NCT04951713 Phase 1 UNKNOWN

This is a phase I study to assess the drug-drug interaction of XZP-3287 and Clarithromycin/Rifampicin. The study also evaluates the pharmacokinetic and tolerability of XZP-3287 in healthy subjects.

Details

Lead sponsor	Xuanzhu Biopharmaceutical Co., Ltd.
Phase	Phase 1
Status	UNKNOWN
Enrolment	60
Start date	2021-07
Completion	2021-12

Conditions

• Healthy

Interventions

• XZP-3287 combined with clarithromycin
• XZP-3287 combined with rifampicin

Primary outcomes

• Primary PK Endpoints — day 1~day 20/day22
  Cmax
• Primary PK Endpoints — day 1~day 20/day22
  AUC0-∞
• Primary PK Endpoints — day 1~day 20/day22
  AUC0-t

Countries

China